Sudarshan Pharma to Acquire 9.5% Stake in US Biotech Firm MedTherapy
Sudarshan Pharma plans to acquire a 9.5% stake in US-based MedTherapy Biotechnology Inc. to expand its presence in the US market. The acquisition, approved by the company's board, involves purchasing over 24 lakh shares for cash and is expected to complete by March 31, 2027, pending regulatory approvals. MedTherapy focuses on affordable cancer treatment, and the partnership aims to leverage biotechnology and manufacturing strengths to create value across global markets.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (65/100). Lens Score 38/100.
Outlets measured: indiatvnews, mint. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
mint broke this story on 6 Sept, 10:19 am. Other outlets followed.